Carbidopa + Entacapone in the Philippines
Quick answer
We could not find carbidopa + entacapone on its own in the FDA Philippines registry data dated 2026-11-05; it appears there only as part of combination products. The DOH price index has no entry for carbidopa + entacapone.
Strengths
Carbidopa + Entacapone by strength
Carbidopa + Entacapone is listed here in 1 strength; none has an FDA-registered product at that exact strength.
| Strength | FDA products |
|---|---|
| Carbidopa + Entacapone 200 mg | not registered |
Sources: FDA Philippines registry (2026-11-05), DOH DPRI June 2024.
About carbidopa + entacapone
Used for
Stalevo-type tablets hold three medicines in one tablet: carbidopa, levodopa and entacapone. The 200 mg in the name is the entacapone part. According to the US FDA label for carbidopa, levodopa and entacapone film-coated tablets, the product treats Parkinson's disease. It is used:
- to replace carbidopa/levodopa and entacapone that a person already takes as separate tablets, at matching strengths
- to replace carbidopa/levodopa alone when its effect wears off before the next dose, in people taking 600 mg of levodopa a day or less and without uncontrolled movements (dyskinesia)
How it works
Parkinson's symptoms are linked to a lack of dopamine in the brain. Levodopa reaches the brain and is turned into dopamine there. Carbidopa stops levodopa from being broken down outside the brain, and entacapone blocks another enzyme (COMT) that breaks it down. Together they let more levodopa reach the brain.
How to take it and usual dose
The dose is set for each person by careful adjustment. Take only one tablet at each dosing time, and do not split the tablets. With the highest strength (50 mg/200 mg/200 mg) the maximum is 6 tablets in 24 hours; with the lower strengths it is 8. Vitamin B6 levels are checked before starting and during treatment. Your doctor decides the dose.
Do not use if
- you take a nonselective MAO inhibitor such as phenelzine or tranylcypromine (it must be stopped at least two weeks before starting)
- you have narrow-angle glaucoma
Common side effects
The most common effects are uncontrolled or extra movements, diarrhea, nausea, belly pain, vomiting, dry mouth and a change in urine color.
Some people suddenly fall asleep during daily activities, even while driving, without feeling sleepy first. Others may get dizziness or fainting on standing, low mood, hallucinations or strong urges and compulsive behavior. Stopping suddenly can cause high fever and confusion, so do not stop on your own.
Source: US FDA label (DailyMed), 2026-04-08. A summary of the official label, not medical advice: your doctor or pharmacist knows your case.
Paying less for carbidopa + entacapone
- Ask for the generic
Prescriptions are written in generic names, and the pharmacist must tell you every brand of that generic and its price. How it works
- Senior or PWD card
20% off plus no VAT on your own medicines, with ID and prescription. What to bring
Questions people ask
Can I buy carbidopa + entacapone in the Philippines?
We could not find carbidopa + entacapone on its own in the FDA Philippines registry data dated 2026-11-05; it appears there only as part of combination products. Medicines sold here must be registered with FDA (RA 9711); ask your doctor or pharmacist.
Is carbidopa + entacapone over the counter in the Philippines?
We could not find carbidopa + entacapone on its own in the FDA Philippines registry data dated 2026-11-05; it appears there only as part of combination products.
Does Stalevo contain levodopa?
Yes. The tablet combines carbidopa, levodopa and entacapone.
Can carbidopa + entacapone tablets be split?
No. The label says not to split the tablets and to take one tablet per dose.
We could not find carbidopa + entacapone on its own in the FDA Philippines registry data dated 2026-11-05; it appears there only as part of combination products. Medicines sold in the Philippines must be registered with FDA (RA 9711).
Data: FDA Philippines registry (checked 2026-11-05), DOH Drug Price Reference Index (June 2024). Sources and method.